MEDICAMEQ Stock Overview
A pharmaceutical company, research, develops, manufactures, markets, sells, and distributes pharmaceutical formulations in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Medicamen Biotech Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹551.95 |
| 52 Week High | ₹630.00 |
| 52 Week Low | ₹355.45 |
| Beta | 1.52 |
| 1 Month Change | 12.06% |
| 3 Month Change | 23.55% |
| 1 Year Change | 8.31% |
| 3 Year Change | -13.30% |
| 5 Year Change | n/a |
| Change since IPO | -0.0091% |
Recent News & Updates
Medicamen Biotech (NSE:MEDICAMEQ) Takes On Some Risk With Its Use Of Debt
Jan 28
What Medicamen Biotech Limited's (NSE:MEDICAMEQ) 27% Share Price Gain Is Not Telling You
Dec 17Recent updates
Medicamen Biotech (NSE:MEDICAMEQ) Takes On Some Risk With Its Use Of Debt
Jan 28What Medicamen Biotech Limited's (NSE:MEDICAMEQ) 27% Share Price Gain Is Not Telling You
Dec 17Medicamen Biotech Limited's (NSE:MEDICAMEQ) P/S Is Still On The Mark Following 41% Share Price Bounce
Sep 28Medicamen Biotech (NSE:MEDICAMEQ) Will Pay A Dividend Of ₹1.00
Sep 03Medicamen Biotech (NSE:MEDICAMEQ) Is Due To Pay A Dividend Of ₹1.00
Aug 16These 4 Measures Indicate That Medicamen Biotech (NSE:MEDICAMEQ) Is Using Debt Extensively
Jul 04What Medicamen Biotech Limited's (NSE:MEDICAMEQ) 28% Share Price Gain Is Not Telling You
May 21More Unpleasant Surprises Could Be In Store For Medicamen Biotech Limited's (NSE:MEDICAMEQ) Shares After Tumbling 26%
Mar 17Medicamen Biotech (NSE:MEDICAMEQ) Will Pay A Dividend Of ₹1.00
Sep 13Why Medicamen Biotech's (NSE:MEDICAMEQ) Shaky Earnings Are Just The Beginning Of Its Problems
Nov 19There's Reason For Concern Over Medicamen Biotech Limited's (NSE:MEDICAMEQ) Price
Dec 03Shareholder Returns
| MEDICAMEQ | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 28.4% | -0.6% | 0.3% |
| 1Y | 8.3% | 7.4% | -1.4% |
Return vs Industry: MEDICAMEQ underperformed the Indian Pharmaceuticals industry which returned 9.4% over the past year.
Return vs Market: MEDICAMEQ exceeded the Indian Market which returned -0.6% over the past year.
Price Volatility
| MEDICAMEQ volatility | |
|---|---|
| MEDICAMEQ Average Weekly Movement | 8.4% |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in IN Market | 9.3% |
| 10% least volatile stocks in IN Market | 4.4% |
Stable Share Price: MEDICAMEQ's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: MEDICAMEQ's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 378 | Rajesh Madan | www.medicamen.com |
Medicamen Biotech Limited, a pharmaceutical company, research, develops, manufactures, markets, sells, and distributes pharmaceutical formulations in India and internationally. The company offers drugs in various forms, including tablet, capsule, oral solution, and drops. Its products are used in therapeutic areas comprising cancer care, cardiology, CNS, diabetology, anti-infective, anti-malarial, vitamins and supplements, other generics, and pain management.
Medicamen Biotech Limited Fundamentals Summary
| MEDICAMEQ fundamental statistics | |
|---|---|
| Market cap | ₹6.96b |
| Earnings (TTM) | ₹73.72m |
| Revenue (TTM) | ₹1.80b |
94.4x
P/E Ratio3.9x
P/S RatioIs MEDICAMEQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEDICAMEQ income statement (TTM) | |
|---|---|
| Revenue | ₹1.80b |
| Cost of Revenue | ₹959.57m |
| Gross Profit | ₹842.97m |
| Other Expenses | ₹769.24m |
| Earnings | ₹73.72m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.80 |
| Gross Margin | 46.77% |
| Net Profit Margin | 4.09% |
| Debt/Equity Ratio | 9.3% |
How did MEDICAMEQ perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield19%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/21 06:02 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medicamen Biotech Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kameswari V. S. Chavali | FirstCall Research |